ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Símbolo de cotizaciónADMA
Nombre de la empresaADMA Biologics Inc
Fecha de salida a bolsaOct 17, 2013
Director ejecutivoMr. Adam S. Grossman
Número de empleados677
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 17
Dirección465 State Route 17
CiudadRAMSEY
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal07446
Teléfono12014785552
Sitio Webhttps://www.admabiologics.com/
Símbolo de cotizaciónADMA
Fecha de salida a bolsaOct 17, 2013
Director ejecutivoMr. Adam S. Grossman
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos